CL2021002878A1 - Tratamiento y prevención de enfermedades metabólicas - Google Patents

Tratamiento y prevención de enfermedades metabólicas

Info

Publication number
CL2021002878A1
CL2021002878A1 CL2021002878A CL2021002878A CL2021002878A1 CL 2021002878 A1 CL2021002878 A1 CL 2021002878A1 CL 2021002878 A CL2021002878 A CL 2021002878A CL 2021002878 A CL2021002878 A CL 2021002878A CL 2021002878 A1 CL2021002878 A1 CL 2021002878A1
Authority
CL
Chile
Prior art keywords
metabolic diseases
prevention
treatment
methods
interleukin
Prior art date
Application number
CL2021002878A
Other languages
English (en)
Spanish (es)
Inventor
Stuart Alexander Cook
Sebastian Schaefer
Anissa Anindya Widjaja
Brijesh Kumars Singh
Original Assignee
Nat Univ Singapore
Singapore Health Serv Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1906291.8A external-priority patent/GB201906291D0/en
Priority claimed from GBGB2001013.8A external-priority patent/GB202001013D0/en
Priority claimed from GBGB2001896.6A external-priority patent/GB202001896D0/en
Priority claimed from GBGB2002030.1A external-priority patent/GB202002030D0/en
Application filed by Nat Univ Singapore, Singapore Health Serv Pte Ltd filed Critical Nat Univ Singapore
Publication of CL2021002878A1 publication Critical patent/CL2021002878A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2073—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5431—IL-11
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL2021002878A 2019-05-03 2021-11-02 Tratamiento y prevención de enfermedades metabólicas CL2021002878A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1906291.8A GB201906291D0 (en) 2019-05-03 2019-05-03 Treatment and prevention of metabolic diseases
GBGB1906597.8A GB201906597D0 (en) 2019-05-03 2019-05-10 Treatment and prevention of metabolic diseases
GBGB2001013.8A GB202001013D0 (en) 2020-01-24 2020-01-24 Treatment and prevention of metabolic diseases
GBGB2001896.6A GB202001896D0 (en) 2020-02-12 2020-02-12 Treatment and prevention of metabolic diseases
GBGB2002030.1A GB202002030D0 (en) 2020-02-14 2020-02-14 Treatment and prevention of metabolic diseases

Publications (1)

Publication Number Publication Date
CL2021002878A1 true CL2021002878A1 (es) 2022-10-07

Family

ID=73051262

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002878A CL2021002878A1 (es) 2019-05-03 2021-11-02 Tratamiento y prevención de enfermedades metabólicas

Country Status (13)

Country Link
US (2) US11813311B2 (enExample)
EP (1) EP3962936A1 (enExample)
JP (1) JP7595028B2 (enExample)
KR (1) KR20220050087A (enExample)
CN (1) CN114364693A (enExample)
AU (1) AU2020268619B2 (enExample)
BR (1) BR112021021921A2 (enExample)
CA (1) CA3146344A1 (enExample)
CL (1) CL2021002878A1 (enExample)
MX (1) MX2021013356A (enExample)
PH (1) PH12021552763A1 (enExample)
TW (1) TW202108606A (enExample)
WO (1) WO2020225147A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12583849B2 (en) 2020-02-28 2026-03-24 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021021921A2 (pt) * 2019-05-03 2021-12-28 Nat Univ Singapore Agente, uso de um agente e método de tratamento ou prevenção de uma doença metabólica
US12400326B2 (en) * 2020-06-09 2025-08-26 Temasek Life Sicences Laboratory Limited Automated disease detection system
CN113041248A (zh) * 2021-04-26 2021-06-29 北京亿药科技有限公司 Ravoxertinib在制备预防和/或治疗非酒精性脂肪性肝病或肝炎药物中的应用
WO2023006765A1 (en) * 2021-07-26 2023-02-02 Boehringer Ingelheim International Gmbh Treatment and prevention of alcoholic liver disease
MX2024002611A (es) * 2021-08-30 2024-05-29 Lassen Therapeutics 1 Inc Anticuerpos anti-il-11ra.
CN114081882B (zh) * 2021-11-15 2023-01-10 中国科学院深圳先进技术研究院 一种a-fabp蛋白抑制剂及其应用
GB202218388D0 (en) 2022-12-07 2023-01-18 Vvb Bio Pte Ltd GP130 antigen-binding molecules
EP4702047A1 (en) 2023-04-25 2026-03-04 VVB Bio Pte. Ltd. Anti il-11 antibody
WO2024259282A2 (en) * 2023-06-15 2024-12-19 The Board Of Trustees Of The Leland Stanford Junior University Interleukin 11 polypeptides and methods of use
GB202311050D0 (en) 2023-07-19 2023-08-30 Vvb Bio Pte Ltd GP130 antigen-binding molecules
GB202405551D0 (en) 2024-04-19 2024-06-05 Vvb Bio Pte Ltd Combination treatment
GB202408044D0 (en) 2024-06-06 2024-07-24 Vvb Bio Pte Ltd gp130 antigen-binding molecules

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
ES2093562B1 (es) 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US6649192B2 (en) 1996-07-29 2003-11-18 Universidade De Santiago De Compostela Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
EP1311277A4 (en) 2000-07-18 2004-08-25 Joslin Diabetes Center Inc METHODS OF FIBROSIS MODULATION
WO2003049693A2 (en) * 2001-12-06 2003-06-19 Wyeth Method and composition for inducing weight loss
US8182814B2 (en) 2007-10-26 2012-05-22 Csl Limited Methods of treating inflammatory airway conditions by inhibition of IL-11 activity
JP5330398B2 (ja) 2007-10-26 2013-10-30 シーエスエル、リミテッド サイトカインムテイン
US8518888B2 (en) 2008-10-14 2013-08-27 Csl Limited Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
TWI452136B (zh) * 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
CN117843785A (zh) * 2013-02-07 2024-04-09 Csl有限公司 Il-11r结合蛋白及其应用
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US20160038589A1 (en) 2014-08-11 2016-02-11 Ophthotech Corporation Methods for treating or preventing ophthalmological conditions
GB201522186D0 (en) * 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
WO2017141032A1 (en) 2016-02-15 2017-08-24 Oxford University Innovation Limited Treatment of fibrotic disorders
GB201621431D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore The Decoy cytokine receptor
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
US20180186871A1 (en) * 2016-12-16 2018-07-05 Singapore Health Services Pte Ltd. Il-11 antibodies
GB201806918D0 (en) 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
GB201809699D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201809700D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
BR112021021921A2 (pt) * 2019-05-03 2021-12-28 Nat Univ Singapore Agente, uso de um agente e método de tratamento ou prevenção de uma doença metabólica

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12583849B2 (en) 2020-02-28 2026-03-24 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use

Also Published As

Publication number Publication date
KR20220050087A (ko) 2022-04-22
BR112021021921A2 (pt) 2021-12-28
JP7595028B2 (ja) 2024-12-06
MX2021013356A (es) 2022-03-11
TW202108606A (zh) 2021-03-01
JP2022531591A (ja) 2022-07-07
US20240156913A1 (en) 2024-05-16
AU2020268619B2 (en) 2026-03-05
CA3146344A1 (en) 2020-11-12
US20200384083A1 (en) 2020-12-10
US20210177940A2 (en) 2021-06-17
US11813311B2 (en) 2023-11-14
AU2020268619A1 (en) 2021-12-16
EP3962936A1 (en) 2022-03-09
WO2020225147A1 (en) 2020-11-12
CN114364693A (zh) 2022-04-15
PH12021552763A1 (en) 2022-07-04

Similar Documents

Publication Publication Date Title
CL2021002878A1 (es) Tratamiento y prevención de enfermedades metabólicas
CL2021002212A1 (es) Tratamiento de lesión renal
CL2021001903A1 (es) Tratamiento de la hepatotoxicidad
CO2021000151A2 (es) Inhibidores de pd-1/pd-l1
MX2023004923A (es) Compuestos heterociclicos como inmunomoduladores.
CL2020002018A1 (es) Composiciones para modular la expresión de c9orf72. (divisional solicitud 201803582)
CO2020009861A2 (es) Inhibidores pd-1/pd-l1
PH12021550187A1 (en) Pyrrolopyrimidine itk inhibitors
MX379543B (es) Purinonas como inhibidores de proteasa específica de ubiquitina 1.
PH12021550698A1 (en) Compositions and methods for treating or preventing diseases and/or disorders caused by exposure to air pollution
MX390535B (es) Compuestos de amino-triazolopiridina y su uso en el trataniento del cancer.
MX2021005887A (es) Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular hemoglobina.
MX2020006128A (es) Inhibidores de la proteina de activacion de fibroblastos.
MX2020010469A (es) Inhibidores del atf6 y sus usos.
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
MX2019010040A (es) Composiciones y métodos para el tratamiento del cáncer.
JOP20230250A1 (ar) تركيبات وطرق لتثبيط إنزيم كيتوهيكسوكيناز (khk)
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
PH12021550671A1 (en) Prodrugs of cgrp antagonists
MX2021013901A (es) Composiciones y métodos para el tratamiento del cáncer.
PH12022550846A1 (en) Thienopyrimidones as trpa1 inhibitors
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.